OakChart

Mangoceuticals Inc

MGRXHealthcare·Health Information Services·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.1993+0.0101 (5.34%)
2026-11-12 03:45 CET
Market cap
4.43 USD m
Revenue, TTM
0.32 USD m
Net income, TTM
-15.99 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-1.17
P/E
-
Compare

Price

MGRX against its 20, 50 and 200-day averages
2050200
0.250.500.751.001.25256.1M512.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MGRXclose 0.2020-day 0.2450-day 0.35200-day 0.390.20

91.3% under the 52-week high of 2.28 on 13 Nov 2025. 52-week low 0.16 on 20 Mar 2026. Last 15 sessions, 66.7% high to low

Volume 0.22× normal · the line is the 50-bar volume average

Profile

MGRX
52-week range, 2% of the way up
0.162.28

Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company was founded on October 7, 2021 and is headquartered in Dallas, TX.

Employees3
IPOMar 21, 2023
Beta2.20
ATR, 14d0.03
Rel volume0.22
Short float0.30%
Insider own21.25%
Inst own7.84%

Snapshot

6 groups

Valuation

Index-
Market Cap4.42M
Enterprise Value4.51M
Income-15.99M
Sales0.32M
Book/sh0.70
Cash/sh0.01
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees3
IPOMar 21, 2023

Ratios

P/E-
Forward P/E-
PEG-
P/S13.83
P/B0.29
P/C19.24
P/FCF-
EV/EBITDA-
EV/Sales14.11
Quick Ratio0.18
Current Ratio0.18
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.17
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-7.77% -244.95%
Sales past 3/5Y270.88% -
EPS Y/Y TTM63.25%
Sales Y/Y TTM-38.91%
EPS Q/Q82.71%
Sales Q/Q-59.10%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own21.25%
Insider Trans0.00%
Inst Own7.84%
Inst Trans10.57%
ROA-85.72%
ROE-94.42%
ROIC-118.21%
Gross Margin-384.90%
Oper. Margin-4272.95%
Profit Margin-5071.14%
SMA20-17.40%
SMA50-43.10%
SMA200-49.35%
Trades-

Technical

Shs Outstand18.02M
Shs Float17.50M
Short Float0.30%
Short Ratio0.04
Short Interest0.05M
52W High2.28 -91.26%
52W Low0.16 23.02%
Volatility13.84% 14.20%
ATR (14)0.03
RSI (14)30.95
Beta2.20
Rel Volume0.22
Avg Volume1.32M
Volume290,683

Performance

Perf Week-3.77%
Perf Month-46.37%
Perf Quarter-62.62%
Perf Half Y-41.38%
Perf YTD-73.07%
Perf Year-88.41%
Perf 3Y-97.05%
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close0.19
Price0.20
Change %5.34%

Peers

Mkt cap
TickerCompanyMkt cap
LFMDLifeMD Inc85.80M
HIMSHims & Hers Health Inc4.86B
MNDRMobile health Network Solutions1.15M
TDOCTeladoc Health Inc1.63B
BTMDbiote Corp60.74M
DRIODarioHealth Corp20.82M
AMWLAmerican Well Corp211.98M
GDRXGoodRx Holdings Inc1.25B
WWWW International Inc130.49M
NNENano Nuclear Energy Inc622.36M

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
JOHNSTON EUGENE MCFODec 15 '25Sale1.173,3333,884120,000Dec 17 05:00 PM
JOHNSTON EUGENE MCFODec 09 '25Sale1.205,0005,975123,333Dec 11 04:05 PM
JOHNSTON EUGENE MCFODec 05 '25Sale1.1310,00011,280128,333Dec 09 05:16 PM
JOHNSTON EUGENE MOfficerDec 03 '25Proposed Sale1.16128,333148,866Dec 03 10:03 AM
Hamilton Alex P.DirectorNov 19 '25Sale1.22125,000152,8753,334Nov 26 04:30 PM
Hamilton Alex P.DirectorNov 19 '25Proposed Sale1.24125,000155,125Nov 19 11:46 AM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 192
  • Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close (GlobeNewswire) -9.15%
  • Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche (GlobeNewswire) +12.24%
  • Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets (GlobeNewswire)
  • Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure (GlobeNewswire) +23.85%
  • Mangoceuticals' Merger Partner, Nuclea Energy ("Nuclea"), Executes MOU with Utah Office of Energy Development (GlobeNewswire) -7.10%
  • Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination (GlobeNewswire) -14.55%
  • Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor (Newsfile) -46.88%
  • Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology (GlobeNewswire)
  • Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc. (GlobeNewswire) -6.95%
  • Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds (GlobeNewswire) -7.02%
  • Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study (GlobeNewswire)
  • Mangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally? (Benzinga) +48.83%
  • Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model (Benzinga)
  • MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.015-1.731-6.451-4.399-2.166-1.172
Period20212022202320242025TTM
EPS, quarterly-1.374-0.993-0.6-1.054-0.543-0.661-0.193-0.224-0.094
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00.0090.7310.6160.4560.32
Period20212022202320242025TTM
Sales, quarterly0.1630.1330.1050.1090.1680.0840.0940.0680.069
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual1.1541.1541.4283.24615.88918.017
Period20212022202320242025MRQ
Shares, quarterly1.9422.1353.2467.14510.64413.88315.88916.96718.017
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.320.460.620.730.010.00
Cost of Goods Sold Incl. D&A1.532.000.960.300.000.00
Gross Profit-1.21-1.54-0.340.430.000.00
Selling, General and Administrative Excl. Other12.2617.618.359.652.000.02
Other Operating Expense0.000.000.000.000.000.00
Operating Income-13.47-19.15-8.69-9.22-1.99-0.02
Interest Expense-0.100.01-0.010.00
Unusual Expense1.261.380.000.000.000.00
Net Income Before Taxes-15.10-20.64-8.71-9.21-2.00-0.02
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-15.10-20.64-8.71-9.21-2.00-0.02
Net Income From Continuing Operations-15.10-20.64-8.71-9.21-2.00-0.02
Net Income-15.99-21.82-8.71-9.21-2.00-0.02
EPS (Recurring)-0.88-2.07-4.40-6.45-1.73-0.02
EPS (Basic, Before Extraordinaries)-1.17-2.17-4.40-6.45-1.73-0.02
EPS (Diluted)-1.17-2.17-4.40-6.45-1.73-0.02
EBITDA-12.08-17.36-7.90-9.19-1.99-0.02
Non-Operating Income (Expense)0.000.000.000.010.000.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense8.3710.792.362.160.08-
Price To Sales Ratio20.6416.347.788.11--
Gross Margin-384.90-338.22-55.4658.9954.26-
Operating Margin-4,272.95-4,200.46-1,411.58-1,260.28-22,279.70-
Net Margin-5,071.14-4,784.65-1,413.63-1,259.40-22,352.11-
Shares Outstanding18.0215.893.251.431.151.15
Market Capitalization4.434.436.024.654.65-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.070.070.090.080.170.110.110.13
Cost of Goods Sold Incl. D&A0.330.340.520.330.370.340.750.05
Gross Profit-0.27-0.28-0.42-0.25-0.20-0.23-0.640.08
Selling, General and Administrative Excl. Other0.773.131.077.295.064.621.761.84
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.03-3.40-1.49-7.54-5.27-4.85-2.40-1.76
Interest Expense0.28-0.020.080.02--0.24
Unusual Expense0.000.001.260.000.130.000.000.00
Net Income Before Taxes-1.31-3.40-2.77-7.62-5.42-4.84-1.95-2.00
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.31-3.40-2.77-7.62-5.42-4.84-1.95-2.00
Net Income From Continuing Operations-1.31-3.40-2.77-7.62-5.42-4.84-1.95-2.00
Net Income-1.61-3.70-3.06-7.62-5.42-4.84-1.95-2.00
EPS (Recurring)-0.09-0.22-0.14-0.66-0.53-1.05-0.60-0.99
EPS (Basic, Before Extraordinaries)-0.09-0.22-0.19-0.66-0.54-1.05-0.60-0.99
EPS (Diluted)-0.09-0.22-0.19-0.66-0.54-1.05-0.60-0.99
EBITDA-0.72-3.10-1.02-7.24-4.97-4.56-1.66-1.71
Non-Operating Income (Expense)0.000.000.000.000.000.010.450.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.091.650.036.603.121.050.470.57
Price To Sales Ratio20.6414.3225.7854.0529.4117.5212.759.44
Gross Margin-386.03-407.27-446.09-297.43-121.65-211.08-609.4561.99
Operating Margin-1,502.45-5,014.65-1,579.46-8,953.45-3,133.98-4,440.00-2,279.58-1,318.21
Net Margin-2,336.71-5,447.88-3,246.68-9,042.82-3,221.61-4,427.38-1,851.22-1,499.04
Shares Outstanding18.0216.9715.8913.8810.647.143.252.13
Market Capitalization4.435.8711.3923.0716.1810.086.027.56

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments1.490.060.740.680.02
Short Term Receivables0.020.000.000.000.00
Inventories0.000.000.020.000.00
Other Current Assets0.040.020.060.010.00
Total Current Assets1.550.080.820.690.02
Net Property, Plant & Equipment0.310.060.220.290.00
Total Investments and Advances0.000.000.000.000.00
Long-Term Note Receivable0.001.15---
Intangible Assets14.2315.230.000.000.00
Other Assets0.000.000.020.020.00
Total Assets16.0916.521.051.000.02
Short Term Debt Incl. Current Port. of LT Debt0.310.210.060.220.04
Accounts Payable0.420.840.140.030.00
Other Current Liabilities0.170.370.010.000.00
Total Current Liabilities0.891.430.210.260.04
Long Term Debt0.000.000.060.130.00
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.000.000.000.00
Total Liabilities0.891.430.280.390.04
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity15.2015.100.770.61-0.02
Total Shareholders Equity15.2015.100.770.61-0.02
Accumulated Minority Interest-0.00-0.000.000.000.00
Total Equity15.2015.100.770.61-0.02
Total Liabilities & Stockholders Equity16.0916.521.051.000.02
Book Value Per Share0.964.650.540.53-0.01
Tangible Book Value Per Share0.06-0.040.540.53-0.01
Full-Time Employees3332-
Price to Book Ratio0.290.383.433.43-
Return on Assets-126.60-99.10-896.99-389.55-
Return on Equity-136.27-109.71-1,326.69-669.02-
Return on Invested Capital-135.80-57.67-1,097.09-269.02-
Quick Ratio1.740.053.792.670.57
Current Ratio1.740.053.882.670.57

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-15.10-20.64-8.71-9.21-2.00-0.02
Depreciation1.821.790.790.020.00-
Other Funds (Non Cash)7.8912.032.392.150.630.00
Funds from Operations-5.39-6.82-5.52-7.04-1.37-0.02
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.500.970.660.040.02-
Cash from Operating Activities-3.89-5.85-4.86-7.00-1.35-0.02
Capital Expenditures0.000.000.00-0.00-0.040.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.070.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.07-0.00-0.040.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock2.965.653.987.222.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.965.653.987.222.000.00
Proceedsfrom Stock Options3.814.733.986.202.000.00
Issuance or Reduction of Debt, Net-0.090.470.15-0.170.050.04
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow1.151.150.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities4.027.274.137.062.050.04
Exchange Rate Effect-0.000.01-0.01---
Net Change in Cash0.131.43-0.680.060.660.02
Free Cash Flow--5.85-4.86-7.00-1.39-0.02
Preferred Dividends (Cash Flow)---0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.230.171.490.480.100.08
Short Term Receivables0.000.020.020.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.020.020.040.120.020.10
Total Current Assets0.250.211.550.600.120.18
Net Property, Plant & Equipment0.280.300.310.010.030.05
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets13.6513.9414.2315.9220.6921.53
Other Assets0.000.000.000.000.000.00
Total Assets14.1714.4516.0916.5321.0721.75
Short Term Debt Incl. Current Port. of LT Debt0.070.060.310.110.630.05
Accounts Payable0.890.530.420.530.771.18
Other Current Liabilities0.440.150.170.170.200.28
Total Current Liabilities1.400.740.890.801.601.50
Long Term Debt0.250.240.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.650.970.890.801.601.50
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity12.5313.4815.2015.7319.4720.25
Total Shareholders Equity12.5313.4815.2015.7319.4720.25
Accumulated Minority Interest-0.00-0.00-0.00-0.00-0.00-0.00
Total Equity12.5213.4715.2015.7319.4720.25
Total Liabilities & Stockholders Equity14.1714.4516.0916.5321.0721.75
Book Value Per Share0.700.790.961.131.832.83
Tangible Book Value Per Share-0.06-0.030.06-0.01-0.12-0.18
Full-Time Employees--3---
Price to Book Ratio0.290.380.651.200.540.42
Return on Assets-85.72-106.11-126.60-125.56-76.14-101.36
Return on Equity-94.42-113.89-136.27-134.99-82.82-115.87
Return on Invested Capital-10.27-24.82-18.22-48.43-27.82-23.90
Quick Ratio0.180.291.740.740.070.12
Current Ratio0.180.291.740.740.070.12

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.31-3.40-2.77-7.62-5.42-4.84
Depreciation0.310.310.900.300.290.29
Other Funds (Non Cash)0.091.68-0.396.513.782.13
Funds from Operations-0.91-1.42-2.26-0.81-1.34-2.42
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.650.111.18-0.430.080.14
Cash from Operating Activities-0.26-1.31-1.08-1.24-1.26-2.27
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.00--
Change in Capital Stock0.270.001.061.620.682.29
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.270.001.061.620.682.29
Proceedsfrom Stock Options0.270.002.211.32-0.621.80
Issuance or Reduction of Debt, Net0.040.00-0.130.000.600.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.001.150.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.320.002.081.621.282.29
Exchange Rate Effect-0.00-0.00-0.00-0.000.000.01
Net Change in Cash0.05-1.311.010.380.020.02
Free Cash Flow---1.08-1.24-1.26-2.27

Revenue breakdown

Services-Misc Health & Allied Services, NEC2024: 615.87K 2025: 456.02K
United States2024: 615.87K 2025: 456.02K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.30%0.1M17.5M11.37M
2026-10-150.52%0.1M17.5M12.63M
2026-09-302.31%0.4M19.0M12.80M
2026-09-152.75%0.5M19.0M13.58M
2026-08-313.45%0.6M18.3M13.37M
2026-08-149.89%1.8M18.3M13.52M
2026-07-3112.90%1.9M14.6M10.61M
2026-07-151.42%0.2M14.6M1.24M
2026-06-302.65%0.4M14.6M1.25M
2026-06-151.84%0.3M14.6M5.92M
2026-05-291.59%0.2M14.6M6.56M
2026-05-152.61%0.4M14.6M12.49M
2026-04-303.16%0.5M14.3M12.55M
2026-04-156.48%0.9M14.3M12.72M
2026-03-317.49%1.0M13.6M12.69M
2026-03-139.39%1.2M13.0M7.36M
2026-02-2713.34%1.7M13.0M6.68M
2026-02-133.31%0.4M13.0M690.11K
2026-01-302.50%0.3M12.8M1.78M
2026-01-154.18%0.5M12.8M1.74M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-06SEC
2026-11-068-KCurrent report2026-11-02SEC
2026-10-098-KCurrent report2026-10-08SEC
2026-10-09424B5SEC
2026-10-064Statement of changes in beneficial ownership of securities2025-09-30SEC
2026-10-06SCHEDULE 13D/ASEC
2026-10-064Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-10-018-KCurrent report2026-09-30SEC
2026-08-218-KCurrent report2026-08-19SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-13425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-06425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-04425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-30425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-30425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-308-KCurrent report2026-07-28SEC
2026-07-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-028-KCurrent report2026-06-29SEC
2026-05-1910-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-15NT 10-Q2026-03-31SEC
2026-04-0110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-31NT 10-K2025-12-31SEC
2026-03-204Statement of changes in beneficial ownership of securities2025-06-05SEC
2026-03-204Statement of changes in beneficial ownership of securities2026-03-16SEC
2026-03-178-KCurrent report2026-03-16SEC
2026-02-238-KCurrent report2026-02-23SEC
2026-02-198-KCurrent report2026-02-19SEC
2026-02-068-KCurrent report2026-02-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120021.14K3
2025-1100152.88K1

Institutional holders

Manager% owned
GEODE CAPITAL MANAGEMENT, LLC3.20%
CITADEL ADVISORS LLC1.97%
XTX Topco Ltd1.08%
Ikarian Capital, LLC0.80%
VANGUARD CAPITAL MANAGEMENT LLC0.72%
VANGUARD FIDUCIARY TRUST CO0.33%
BOOTHBAY FUND MANAGEMENT, LLC0.22%
NORTHERN TRUST CORP0.22%
HRT FINANCIAL LP0.21%
Ackerman Capital Advisors, LLC0.16%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund2.72%
VANGUARD EXTENDED MARKET INDEX FUND0.72%
Fidelity Extended Market Index Fund0.35%
Fidelity Series Total Market Index Fund0.07%
Fidelity Total Market Index Fund0.06%

OakChart. MGRX. Cached 15 minutes.

Some panels did not load: ratings.